证券记录 · 已归档季度
ACRS
Aclaris Therapeutics, Inc. · Healthcare · Biotechnology
13被追踪持有人
0Δ持有人
38.17M持有股份
$54.21M报告持仓市值
+0新建仓位
−0清仓
动量输入（同类管理人）： 持有人广度 0.0% · 股份流向 +5.3% · 净新建仓位 0.0% — 公式
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 61 | -2 | 42.13M | $222.66M | +3 | −5 |
| Q1 2026 | 65 | -2 | 41.75M | $156.42M | +5 | −7 |
| Q4 2025 | 67 | +2 | 40.44M | $121.72M | +2 | — |
| Q3 2025 | 17 | +1 | 36.82M | $69.96M | +1 | — |
| Q2 2025 | 13 | 0 | 38.17M | $54.21M | — | — |
| Q1 2025 | 10 | 0 | 23.63M | $36.15M | — | — |
| Q4 2024 | 10 | +2 | 20.49M | $50.82M | +2 | — |
| Q3 2024 | 7 | -1 | 10.01M | $11.51M | — | −1 |
| Q2 2024 | 8 | — | 10.87M | $11.95M | — | — |
持有人 · Q2 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 9.63M | 0.0% | $13.67M | 0.0% | Held | 3 | SEC ↗ |
| 2 | The Vanguard Group ✦ (被动) | 6.66M | — | $9.46M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | The Vanguard Group ✦ (被动) | 6.66M | — | $9.46M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | The Vanguard Group ✦ (被动) | 6.66M | — | $9.46M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | BlackRock ✦ (被动) | 5.51M | — | $7.83M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | BlackRock ✦ (被动) | 5.51M | — | $7.83M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | BlackRock ✦ (被动) | 5.51M | — | $7.83M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | BlackRock ✦ (被动) | 5.51M | — | $7.83M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | BlackRock ✦ (被动) | 5.51M | — | $7.83M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | BlackRock ✦ (被动) | 5.51M | — | $7.83M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | BlackRock ✦ (被动) | 5.51M | — | $7.83M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Millennium Management ✦ | 3.84M | -7.2% | $5.45M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 2.80M | -4.9% | $3.98M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 2.80M | -4.9% | $3.98M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 15 | Geode Capital Management ✦ (被动) | 2.46M | +108.4% | $3.50M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 16 | Geode Capital Management ✦ (被动) | 2.46M | +108.4% | $3.50M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 17 | Marshall Wace ✦ | 2.29M | -0.9% | $3.26M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | Marshall Wace ✦ | 2.29M | -0.9% | $3.26M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 19 | Renaissance Technologies ✦ | 1.46M | +54.0% | $2.08M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 20 | Citadel Advisors ✦ | 1.14M | +1.9% | $1.62M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 21 | Citadel Advisors ✦ | 1.14M | +1.9% | $1.62M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 22 | State Street Global Advisors ✦ (被动) | 1.01M | +147.1% | $1.43M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 23 | Two Sigma Investments ✦ | 749.66K | -8.6% | $1.06M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 24 | Fidelity (FMR) ✦ | 442.25K | — | $627,991 | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Fidelity (FMR) ✦ | 442.25K | — | $627,991 | 0.0% | n/c | 1 | SEC ↗ |
| 26 | T. Rowe Price ✦ | 166.37K | +35.1% | $237,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 135 持有人, 108.23M 股份, $397.63M 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2025 ·
方法论 ·
通过API获取此数据